118 related articles for article (PubMed ID: 11104612)
1. The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer.
Deng X; Høgdall EV; Høgdall CK; Nørgaard-Pedersen B; Jørgensen M; Nielsen H; Engelholm SA
Gynecol Oncol; 2000 Dec; 79(3):416-9. PubMed ID: 11104612
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
Høgdall CK; Nørgaard-Pedersen B; Mogensen O
Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
[TBL] [Abstract][Full Text] [Related]
3. Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
Begum FD; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Christensen L; Høgdall C
Acta Obstet Gynecol Scand; 2010; 89(2):190-8. PubMed ID: 20121334
[TBL] [Abstract][Full Text] [Related]
4. Human tetranectin: methodological and clinical studies.
Høgdall CK
APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
[TBL] [Abstract][Full Text] [Related]
5. Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients.
Begum FD; Høgdall E; Christensen IJ; Christensen L; Kjaer SK; Blaakaer J; Petri AL; Høgdall C
Gynecol Oncol; 2010 Jun; 117(3):446-50. PubMed ID: 20304468
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
van Dalen A; Favier J; Burges A; Hasholzner U; de Bruijn HW; Dobler-Girdziunaite D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
Gynecol Oncol; 2000 Dec; 79(3):444-50. PubMed ID: 11104617
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
8. Serum tetranectin and CA125 in endometrial adenocarcinoma.
Lundstrøm MS; Høgdall CK; Nielsen AL; Nyholm HC
Anticancer Res; 2000; 20(5C):3903-6. PubMed ID: 11268474
[TBL] [Abstract][Full Text] [Related]
9. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Markman M; Federico M; Liu PY; Hannigan E; Alberts D
Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
[TBL] [Abstract][Full Text] [Related]
10. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.
Makar AP; Kristensen GB; Kaern J; Børmer OP; Abeler VM; Tropé CG
Obstet Gynecol; 1992 Jun; 79(6):1002-10. PubMed ID: 1579296
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF
Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of Ca 125 levels during primary therapy.
Markmann S; Gerber B; Briese V
Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
[TBL] [Abstract][Full Text] [Related]
15. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
16. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer.
Kang S; Seo SS; Park SY
J Surg Oncol; 2009 Sep; 100(3):244-7. PubMed ID: 19267361
[TBL] [Abstract][Full Text] [Related]
17. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
[TBL] [Abstract][Full Text] [Related]
18. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
19. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors.
Høgdall CK; Mogensen O; Tabor A; Mogensen B; Jakobsen AK; Nørgaard-Pedersen B; Larsen SO; Clemmensen I
Gynecol Oncol; 1995 Jan; 56(1):22-8. PubMed ID: 7821842
[TBL] [Abstract][Full Text] [Related]
20. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]